{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:43Z","timestamp":1793643343989,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Invasive pulmonary aspergillosis (IPA) is an increasingly recognized complication in intensive care unit (ICU) patients, especially those with influenza, cirrhosis, chronic obstructive pulmonary disease, and other diseases. The diagnosis can be challenging, especially in the ICU, where clinical symptoms as well as imaging are mostly nonspecific. Recently, <jats:italic>Aspergillus<\/jats:italic> lateral flow tests were developed to decrease the time to diagnosis of IPA. Several studies have shown promising results in bronchoalveolar lavage fluid (BALf) from hematology patients. We therefore evaluated a new lateral flow test for IPA in ICU patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Using left-over BALf from adult ICU patients in two university hospitals, we studied the performance of the <jats:italic>Aspergillus<\/jats:italic> galactomannan lateral flow assay (LFA) by IMMY (Norman, OK, USA). Patients were classified according to the 2008 EORTC-MSG definitions, the AspICU criteria, and the modified AspICU criteria, which incorporate galactomannan results. These internationally recognized consensus definitions for the diagnosis of IPA incorporate patient characteristics, microbiology and radiology. The LFA was read out visually and with a digital reader by researchers blinded to the final clinical diagnosis and IPA classification.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We included 178 patients, of which 55 were classified as cases (6 cases of proven and 26 cases of probable IPA according to the EORTC-MSG definitions, and an additional 23 cases according to the modified AspICU criteria). Depending on the definitions used, the sensitivity of the LFA was 0.88\u20130.94, the specificity was 0.81, and the area under the ROC curve 0.90\u20130.94, indicating good overall test performance.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In ICU patients, the LFA performed well on BALf and can be used as a rapid screening test while waiting for other microbiological results.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13054-020-03367-7","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T03:02:33Z","timestamp":1604977353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Point of care aspergillus testing in intensive care patients"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-6426","authenticated-orcid":false,"given":"Toine","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Veldhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Holtappels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"3367_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Tienen CV, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782\u201392.","journal-title":"Lancet Respir Med"},{"key":"3367_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","volume":"170","author":"W Meersseman","year":"2004","unstructured":"Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerdert E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"3367_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","volume":"19","author":"FS Taccone","year":"2015","unstructured":"Taccone FS, Van den Abeele A-M, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.","journal-title":"Crit Care"},{"key":"3367_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/myc.13096","volume":"63","author":"P Koehler","year":"2020","unstructured":"Koehler P, Cornely OA, B\u00f6ttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:528\u201334.","journal-title":"Mycoses"},{"key":"3367_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30237-X","author":"A Alanio","year":"2020","unstructured":"Alanio A, Delli\u00e8re S, Fodil S, Bretagne S, M\u00e9garbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020. https:\/\/doi.org\/10.1016\/S2213-2600(20)30237-X.","journal-title":"Lancet Respir Med."},{"key":"3367_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.4065\/75.6.562","volume":"75","author":"J Roosen","year":"2000","unstructured":"Roosen J, Frans E, Wilmer A, Knockaert DC, Bobbaers H. Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings. Mayo Clin Proc. 2000;75:562\u20137.","journal-title":"Mayo Clin Proc"},{"key":"3367_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina EE, Abril E, Padilla R, Ru\u00edz CR, Ballen A, Frutos-Vivar F, et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses. 2019;62:673\u20139.","journal-title":"Mycoses"},{"key":"3367_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B de Pauw","year":"2008","unstructured":"de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"3367_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"SI Blot","year":"2012","unstructured":"Blot SI, Taccone FS, Van den Abeele A-M, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"3367_CR10","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/jac\/dkx030","volume":"72","author":"F Lamoth","year":"2017","unstructured":"Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease. J Antimicrob Chemother. 2017;72:i19-28.","journal-title":"J Antimicrob Chemother"},{"key":"3367_CR11","doi-asserted-by":"publisher","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","volume":"7","author":"M Zou","year":"2012","unstructured":"Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE. 2012;7:e43347.","journal-title":"PLoS ONE"},{"key":"3367_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1378\/chest.10-0488","volume":"138","author":"Y-L Guo","year":"2010","unstructured":"Guo Y-L, Chen Y-Q, Wang K, Qin S-M, Wu C, Kong J-L. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest. 2010;138:817\u201324.","journal-title":"Chest"},{"key":"3367_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/1040841X.2013.804033","volume":"41","author":"SC Heng","year":"2015","unstructured":"Heng SC, Morrissey O, Chen SC-A, Thursky K, Manser RL, Nation RL, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis. Crit Rev Microbiol. 2015;41:124\u201334.","journal-title":"Crit Rev Microbiol"},{"key":"3367_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","volume":"177","author":"W Meersseman","year":"2008","unstructured":"Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"3367_CR15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/myc.12788","volume":"61","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Br\u00fcggemann RJ, Biemond BJ, et al. The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. Mycoses. 2018;61:656\u201364.","journal-title":"Mycoses"},{"key":"3367_CR16","doi-asserted-by":"publisher","first-page":"1563.e1","DOI":"10.1016\/j.cmi.2019.08.009","volume":"25","author":"C Lass-Fl\u00f6rl","year":"2019","unstructured":"Lass-Fl\u00f6rl C, Cascio GL, Nucci M, dos Santos MC, Colombo AL, Vossen M, et al. Respiratory specimens and the diagnostic accuracy of Aspergillus lateral flow assays (LFA-IMMYTM): real-life data from a multicentre study. Clin Microbiol Infect Elsevier. 2019;25:1563.e1-1563.e3.","journal-title":"Clin Microbiol Infect Elsevier"},{"key":"3367_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/mmy\/myz079","volume":"58","author":"T Mercier","year":"2019","unstructured":"Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study. Med Mycol. 2019;58:444\u201352.","journal-title":"Med Mycol."},{"key":"3367_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-015-0905-x","volume":"19","author":"S Eigl","year":"2015","unstructured":"Eigl S, Prattes J, Lackner M, Willinger B, Spiess B, Reinwald M, et al. Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Crit Care Lond Engl. 2015;19:178.","journal-title":"Crit Care Lond Engl"},{"key":"3367_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jinf.2018.10.014","volume":"78","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R, Law N, Reed SL, Hoenigl M. Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies. J Infect. 2019;78:249\u201359.","journal-title":"J Infect"},{"key":"3367_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1553-2712.1996.tb03538.x","volume":"3","author":"NMF Buderer","year":"1996","unstructured":"Buderer NMF. Statistical methodology: I. incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3:895\u2013900.","journal-title":"Acad Emerg Med."},{"key":"3367_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/myc.12881","volume":"62","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage. Mycoses. 2019;62:230\u20136.","journal-title":"Mycoses"},{"key":"3367_CR22","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1086\/647935","volume":"49","author":"J Maertens","year":"2009","unstructured":"Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688\u201393.","journal-title":"Clin Infect Dis"},{"key":"3367_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2019;71:1367\u201376.","journal-title":"Clin Infect Dis."},{"key":"3367_CR24","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","volume":"46","author":"PE Verweij","year":"2020","unstructured":"Verweij PE, Rijnders BJA, Br\u00fcggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46:1524\u201335.","journal-title":"Intensive Care Med."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-020-03367-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T03:12:29Z","timestamp":1604977949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-03367-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1186\/s13054-020-03367-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Due to the retrospective nature of this study on remaining fractions of previously collected samples for diagnostic purposes, the need for informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS received non-financial support from Gilead Sciences and Pfizer and served as a consultant for Gilead Sciences. BR declares research grants from Gilead and travel support from Gilead. Payments for advisory board participation for Pfizer, Gilead, MSD, F2G. All outside the context of the submitted work. JM has received grant support from Bio-Rad Laboratories, Merck Sharp and Dohme, Gilead Sciences, Pfizer and Schering-Plough; has been an advisor\/consultant for Bio-Rad Laboratories, Fujisawa Healthcare, Gilead Sciences, Merck Sharp and Dohme, Nektar Therapeutics, Pfizer, Schering-Plough, Cidara, Scynexis and F2G; and has been on the speakers' bureau for Bio-Rad Laboratories, Fujisawa Healthcare, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering-Plough, Cidara and F2G. JW declares research grants from MSD\/Pfizer and travel support and speakers' fee from Gilead\/MSD\/Pfizer, all outside the context of the submitted work. TM received an unrestricted research grant from Gilead Sciences, served as a consultant for Gilead Sciences, Pfizer and Celgene, and received non-financial support from MSD\/Merck, Gilead Sciences, Pfizer, OLM Diagnostics, IMMY and FUJIFILM Wako. AD, MH and VV have no conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"642"}}